Journal
ACTA PHARMACOLOGICA SINICA
Volume 41, Issue 7, Pages 970-985Publisher
NATURE PUBL GROUP
DOI: 10.1038/s41401-020-0424-4
Keywords
cancer immunotherapy; tumor microenvironment; immunosuppression; immune cells; cytokines; enzymes; nanomedicine
Funding
- National Institutes of Health [U54CA198999, R01 CA178748]
- Department of Defense Congressionally Directed Medical Research Programs-Peer Reviewed Cancer Research Program Idea Award [CA150391]
- University of North Carolina Research Opportunity Initiative grant
Ask authors/readers for more resources
Cancer immunotherapy has received extensive attention due to its ability to activate the innate or adaptive immune systems of patients to combat tumors. Despite a few clinical successes, further endeavors are still needed to tackle unresolved issues, including limited response rates, development of resistance, and immune-related toxicities. Accumulating evidence has pinpointed the tumor microenvironment (TME) as one of the major obstacles in cancer immunotherapy due to its detrimental impacts on tumor-infiltrating immune cells. Nanomedicine has been battling with the TME in the past several decades, and the experience obtained could be exploited to improve current paradigms of immunotherapy. Here, we discuss the metabolic features of the TME and its influence on different types of immune cells. The recent progress in nanoenabled cancer immunotherapy has been summarized with a highlight on the modulation of immune cells, tumor stroma, cytokines and enzymes to reverse the immunosuppressive TME.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available